No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AKRO241220P5000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV82.96%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.11Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
Akero a New Buy at Citi on Liver Disease Asset
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup